YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial. This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results